胃癌免疫检查点抑制剂疗法:当前状况,治疗挑战和未来前景
Penghui Liu1, Na Li1, Jiwu Guo1
1Lanzhou University Second Hospital, The General Surgery Department, Lanzhou, China.
Frontiers in immunology
|March 16, 2026
概括
免疫检查点抑制剂 (ICI) 通过增强免疫反应,对胃癌治疗有希望. 然而,耐药性和副作用等挑战需要进一步研究个性化免疫疗法策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 胃癌是全球领先的消化系统恶性瘤.
- 针对PD-1/PD-L1和CTLA-4通路的免疫检查点抑制剂 (ICI) 已经推进了胃癌治疗.
- 尽管取得了进展,但重大挑战阻碍了ICI在胃癌中的有效性.
研究的目的:
- 审查基于ICI的胃癌治疗的最新进展.
- 分析与ICI相关的当前临床挑战.
- 突出未来的研究方向,以优化胃癌免疫疗法.
主要方法:
- 关于胃癌中ICI的当前文献的叙事综述.
- 分析治疗耐药性,不良事件,生物标志物和瘤微环境.
- 确定未来研发的关键领域.
主要成果:
- 通过增强抗瘤免疫力,ICI提供了新的治疗选择.
- 关键的挑战包括治疗耐药性,与免疫相关的不良事件,缺乏生物标志物和免疫抑制瘤微环境.
- 未来的方向包括生物标志物发现,预测模型,组合疗法,耐药性向,微生物群调节和毒性管理.
结论:
- 推进胃癌免疫疗法需要解决当前的挑战.
- 未来的努力应专注于个性化,基于精度的方法,以获得最大的有效性和安全性.
- 优化ICI治疗有可能在胃癌治疗中取得重大突破.
更多相关视频
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.6K
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.6K
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
723
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
723
Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Mitogens and the Cell Cycle
8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Peptic Ulcer Disease IV: Management
612
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
612
